Bisolvon 10mg/g Oral Powder

Šalis: Airija

kalba: anglų

Šaltinis: HPRA (Health Products Regulatory Authority)

Veiklioji medžiaga:

Bromhexine hydrochloride

Prieinama:

Boehringer Ingelheim Ltd

ATC kodas:

QR05CB02

INN (Tarptautinis Pavadinimas):

Bromhexine hydrochloride

Dozė:

10 milligram(s)/gram

Vaisto forma:

Oral powder

Recepto tipas:

POM: Prescription Only Medicine as defined in relevant national legislation

Farmakoterapinė grupė:

Cats, Cattle, Dogs, Pigs

Gydymo sritis:

bromhexine

Terapinės indikacijos:

Respiratory Tract preparations

Autorizacija statusas:

Authorised

Leidimo data:

1991-10-01

Prekės savybės

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Bisolvon 10mg/g Oral Powder
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gram contains:
Active Substance
Bromhexine Hydrochloride
10 mg
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder for oral solution or addition to feed.
White crystalline powder.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle, pigs, dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
As an aid to the treatment of respiratory disease in cattle, pigs,
dogs and cats where mucus is a complicating factor.
4.3 CONTRAINDICATIONS
Not for use in cows producing milk for human consumption.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
Avoid contact with the skin and eyes. In case of accidental eye
contact, flush the affected eye with copious amounts of
clean running water.
Wash hands and exposed skin after administering the product.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_7_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_2_
_4_
_2_
_3_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None known.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
Not applicable.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
Ma